Foley Hoag LLP advised Alloy Therapeutics on the deal.
Alloy Therapeutics announced a $75 million Series C Financing. Proceeds from the Series C financing will support the extension of Alloy’s platforms and services into adjacent biologic modalities and further expand access to Alloy’s capabilities to more partners and geographies around the world. The round was led by 8VC, Presight Capital and Peter Thiel, with participation from new investors including Mubadala Capital, an unnamed sovereign wealth fund, Founders Fund and Gaingels, as well as existing investors Luma Bio-IT, Alexandria Venture Investments and Ulysses Diversified Holdings.
Headquartered in Boston, MA, with European labs in Cambridge, UK, Alloy is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners, Alloy democratizes access to tools, technologies, services and company creation capabilities that are foundational for discovering and developing therapeutic biologics. The company’s lead offering, the ATX-Gx™ platform, is a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains.
Foley Hoag attorneys Patrick Connolly (Picture), Kevin Lin, Mark Potash and Sarah Ropiak represented Alloy in the transaction, with support at key intervals from Earl Mellott, Chasse Osborn, Luciano Racco and Austin Ownbey.
Involved fees earner: Ian Chasse Osborn – Foley Hoag; Patrick Connolly – Foley Hoag; Kevin Lin – Foley Hoag; Earl Mellott – Foley Hoag; Austin Ownbey – Foley Hoag; Mark Potash – Foley Hoag; Luciano Racco – Foley Hoag; Sarah Ropiak – Foley Hoag;
Law Firms: Foley Hoag;
Clients: Alloy Therapeutics;